Dingivan Christine A 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Jun 18, 2010
Insider Transaction Report
Form 4
Dingivan Christine A
EVP/Chief Medical Officer
Transactions
- Award
Stock Option (to buy)
2010-06-17+20,000→ 20,000 totalExercise: $26.64From: 2011-06-17Exp: 2020-06-17→ Common Stock (20,000 underlying)
Holdings
- 7,763
Stock Options (to buy)
Exercise: $37.69From: 2009-10-03Exp: 2018-10-03→ Common Stock (7,763 underlying) - 31,052
Stock Options (to buy)
Exercise: $25.74From: 2010-02-18Exp: 2019-02-18→ Common Stock (31,052 underlying) - 41,403
Stock Option (to buy)
Exercise: $20.45From: 2011-02-25Exp: 2020-02-25→ Common Stock (41,403 underlying) - 7,763
Stock Options (to buy)
Exercise: $19.94From: 2009-11-20Exp: 2018-11-20→ Common Stock (7,763 underlying) - 93,156
Stock Options (to buy)
Exercise: $36.65From: 2009-07-28Exp: 2018-07-28→ Common Stock (93,156 underlying)
Footnotes (7)
- [F1]The options will vest in equal increments of 1/3 on June 17, 2011, June 17 2012 and June 17, 2013.
- [F2]Exercise price and share amounts reflect an anti-dilution adjustment made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.
- [F3]The options will vest in equal increments of 1/3 on February 25, 2011, February 25, 2012 and February 25, 2013.
- [F4]The options will vest in equal increments of 1/3 on February 18, 2010, February 18, 2011 and February 18, 2012.
- [F5]The options will vest in equal increments of 1/3 on November 20, 2009, November 20, 2010 and November 20, 2011.
- [F6]The options will vest in equal increments of 1/3 on October 3, 2009, October 3, 2010 and October 3, 2011.
- [F7]The options vest in equal increments of 1/3 on July 28, 2009, July 28, 2010 and July 28, 2011.